Does stress-axis cortisol signaling raise blood glucose and triglycerides?

Stress-axis activation coordinates a metabolic shift designed to mobilize energy substrates, but chronic or excessive cortisol signaling can severely disrupt systemic glucose and lipid homeostasis.

Glucose mobilization and hyperglycemia

• Genomic pathway activation: Cortisol binds to hepatocyte glucocorticoid receptors, directly driving the transcription of rate-limiting gluconeogenic enzymes, specifically phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase). This genomic program is highly coordinated by transcriptional coactivators like FoxO1, CREB, and PGC-1α.
• Systemic accumulation: The resulting increase in hepatic glucose output directly elevates blood glucose. This hyper-glycemic state is further compounded by cortisol-induced insulin resistance, which limits glucose clearance in peripheral tissues like skeletal muscle.

Lipid mobilization and hypertriglyceridemia

• Lipolytic stimulation: In adipose tissue, cortisol upregulates and activates key lipolytic enzymes, primarily adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL), which accelerates the hydrolysis of stored fat and releases free fatty acids (FFAs) into the blood.
• Hepatic re-esterification: The liver acts as a sink for these circulating FFAs. Instead of entering beta-oxidation, this massive influx of fatty acids is re-esterified into triglycerides, assembled into very-low-density lipoproteins (VLDL-TG), and secreted back into the circulation, causing hypertriglyceridemia.

The metabolic cross-talk

• Fueling gluconeogenesis: There is a direct functional link between these two pathways. The hepatic oxidation of mobilized FFAs provides the necessary ATP and reducing equivalents required to power energy-intensive gluconeogenesis, creating a feed-forward cycle of elevated glucose and lipids.

Bottom line

• Stress-axis cortisol signaling drives hyperglycemia and hypertriglyceridemia by upregulating rate-limiting enzymes of gluconeogenesis (PEPCK/G6Pase) and lipolysis (ATGL/HSL), establishing a dual pathway where mobilized fatty acids both fuel hepatic glucose production and drive VLDL-triglyceride secretion.